data_2knp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2knp _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.464 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.4 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.464 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.573 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.573 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.606 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.616 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.426 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.426 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.616 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.606 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.417 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.609 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.417 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.501 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.569 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.577 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.577 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.569 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.611 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.611 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.671 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.574 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.597 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.516 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.516 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.597 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.671 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.454 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.771 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.465 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.517 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.609 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.573 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.426 HG21 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.465 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.771 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.609 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.617 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.617 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.509 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.414 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.625 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.514 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.586 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.665 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.498 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.571 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.581 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.4 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.54 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.54 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.586 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.581 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.665 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.571 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.468 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.623 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.403 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.623 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.845 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p . . . . . 0 N--CA 1.455 -0.194 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.46 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.845 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.43 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.681 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.43 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.681 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.456 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.643 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.497 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.497 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.609 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.46 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.643 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.54 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.589 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.487 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.565 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.565 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.604 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.512 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.458 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.512 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.547 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.589 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.439 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.55 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.538 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.708 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.708 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.543 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.697 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.588 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.531 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.697 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.588 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.553 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.775 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.404 ' HA ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.775 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.668 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.591 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.427 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.427 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.591 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.668 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t . . . . . 0 N--CA 1.457 -0.099 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.622 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.443 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.756 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.421 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.511 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.421 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.622 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.464 ' HG ' ' CD ' ' A' ' 3' ' ' GLU . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.434 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.692 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.487 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.695 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.507 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.555 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.447 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.447 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.415 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.695 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.555 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.507 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.61 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 6' ' ' GLN . 5.9 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.61 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.513 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.649 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.564 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.46 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m . . . . . 0 CA--C 1.519 -0.235 0 CA-C-O 120.744 0.307 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HZ1' ' HA ' ' A' ' 2' ' ' CYS . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.871 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.871 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.534 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.506 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.556 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.419 HG21 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.419 ' HA2' HG21 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.534 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.621 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.406 0.146 . . . . 0.0 111.305 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.684 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.621 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.423 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.423 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.684 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.64 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.759 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.412 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.412 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.605 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.445 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.445 ' H ' ' HB ' ' A' ' 22' ' ' THR . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.4 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.403 ' HA ' ' HA3' ' A' ' 8' ' ' GLY . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.759 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.609 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.605 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.572 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.572 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.473 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.647 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.466 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.645 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.443 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.443 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.601 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.489 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m . . . . . 0 N--CA 1.454 -0.258 0 CA-C-O 120.685 0.278 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.69 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.814 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.552 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.684 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.575 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.485 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.69 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.575 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.543 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.521 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.543 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.476 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.567 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.567 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.583 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.606 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.46 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.523 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.46 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.606 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.434 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.583 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.456 ' H3 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.483 1.802 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -130.67 36.71 3.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.464 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.4 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.464 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.573 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.573 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.606 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.616 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.426 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.426 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.616 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.464 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.606 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.8 0 N-CA-C 112.225 -0.35 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.417 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t -84.5 -22.28 30.28 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.609 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.417 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.501 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.569 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.577 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.577 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.569 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.563 ' H2 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.97 43.89 2.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.563 ' CD ' ' H2 ' ' A' ' 1' ' ' GLY . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.611 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.611 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.671 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.574 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.597 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.516 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.516 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.597 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.671 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.007 -0.437 . . . . 0.0 112.007 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.454 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t -111.88 23.77 13.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.771 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.465 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.517 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.609 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.573 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.426 HG21 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.465 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.771 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.609 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.787 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t -106.97 22.41 16.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.617 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.617 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.509 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.414 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.625 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.514 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.598 ' H3 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.586 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER -114.5 27.73 9.25 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.665 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.498 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.571 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.581 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.4 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.54 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.54 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.586 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.581 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.665 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.571 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.559 ' H2 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -119.95 34.57 5.16 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.559 ' CD ' ' H2 ' ' A' ' 1' ' ' GLY . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.468 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.623 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.403 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.623 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.065 0 N-CA-C 112.68 -0.168 . . . . 0.0 112.68 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.845 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p -120.67 21.89 11.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.46 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.845 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.43 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.681 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.43 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.681 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.456 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.643 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.497 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.497 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.609 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.46 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.643 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.609 ' H2 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.485 1.926 0 N-CA-C 111.841 -0.503 . . . . 0.0 111.841 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.54 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -114.71 23.14 12.92 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.609 ' CD ' ' H2 ' ' A' ' 1' ' ' GLY . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.487 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.565 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.565 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.547 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.604 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.512 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.458 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.512 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.547 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.589 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.439 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 112.061 -0.416 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.55 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t -117.84 15.14 14.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.538 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.708 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.708 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.543 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.697 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.588 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.531 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.697 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.588 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.553 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m -82.65 -15.69 51.08 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 -179.334 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.489 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.775 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.404 ' HA ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.775 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.489 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.668 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.591 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.427 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.427 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.591 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.668 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.985 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t -130.67 -1.72 4.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.622 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.443 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.756 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.421 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.511 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.421 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.622 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.464 ' HG ' ' CD ' ' A' ' 3' ' ' GLU . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.434 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.553 ' H3 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.484 1.874 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p -118.82 39.02 3.62 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.553 ' CD ' ' H3 ' ' A' ' 1' ' ' GLY . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.692 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.487 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.695 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.507 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.555 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.447 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.447 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.415 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.487 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.695 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.555 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.507 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' H2 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.997 0 N-CA-C 112.092 -0.403 . . . . 0.0 112.092 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t -100.83 -10.84 20.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.61 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.404 HE21 ' HB2' ' A' ' 6' ' ' GLN . 5.9 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.61 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.513 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.649 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.564 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.46 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.507 ' H1 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.993 0 N-CA-C 112.229 -0.348 . . . . 0.0 112.229 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m -123.47 26.01 8.03 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 122.583 -0.363 . . . . 0.0 111.154 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.507 ' CD ' ' H1 ' ' A' ' 1' ' ' GLY . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HZ1' ' HA ' ' A' ' 2' ' ' CYS . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.871 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.871 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.534 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.506 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.556 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.419 HG21 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.419 ' HA2' HG21 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.501 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.534 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.35 -0.3 . . . . 0.0 112.35 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.621 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t -86.3 -20.53 28.23 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 122.789 -0.242 . . . . 0.0 111.305 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.684 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.712 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.621 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.423 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.423 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.712 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.684 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.64 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.48 ' H3 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t -106.93 29.24 7.22 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.48 ' CD ' ' H3 ' ' A' ' 1' ' ' GLY . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.759 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.412 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.412 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.605 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.445 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.445 ' H ' ' HB ' ' A' ' 22' ' ' THR . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.4 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.403 ' HA ' ' HA3' ' A' ' 8' ' ' GLY . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.759 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.609 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.605 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.551 ' H3 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.484 1.856 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER -118.5 43.83 2.4 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 179.311 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.551 ' CD ' ' H3 ' ' A' ' 1' ' ' GLY . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.572 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.572 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.473 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.647 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.466 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.645 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.443 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.443 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.645 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.601 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.534 ' H2 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.489 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m -113.81 29.73 7.78 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.641 -0.329 . . . . 0.0 110.785 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.534 ' CD ' ' H2 ' ' A' ' 1' ' ' GLY . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.69 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.814 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.552 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.684 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.575 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.485 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.69 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.575 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.518 ' H1 ' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.488 2.111 0 N-CA-C 112.333 -0.307 . . . . 0.0 112.333 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.543 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p -122.84 -17.53 6.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.521 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.543 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.476 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.567 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.567 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.583 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.606 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.46 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.523 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.46 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.606 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.434 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.583 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.635 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.583 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.613 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.688 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.433 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.552 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.552 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.472 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.688 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.477 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.613 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.742 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.414 ' HA ' ' HD2' ' A' ' 25' ' ' PRO . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.742 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.584 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.402 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.744 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.52 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.744 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.686 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.525 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.814 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.429 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.814 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.611 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 9' ' ' LEU . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.619 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.634 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.514 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.716 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.716 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.671 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.418 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.463 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.575 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.756 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.415 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.415 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.549 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.549 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.607 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.756 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.671 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.575 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.482 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.627 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.41 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.627 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.868 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p . . . . . 0 N--CA 1.455 -0.194 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.446 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.868 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.45 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.669 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.45 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.669 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.647 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.66 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.508 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.508 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.66 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.446 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.647 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.606 ' HG2' ' HA ' ' A' ' 32' ' ' SER . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.565 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.534 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.514 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.481 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.514 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.534 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.606 ' HA ' ' HG2' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.454 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.554 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.704 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.704 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.671 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.769 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.769 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.614 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.818 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.818 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.688 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t . . . . . 0 N--CA 1.457 -0.099 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.755 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.755 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.55 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.423 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.518 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.423 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.636 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.458 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.683 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.494 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.722 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.553 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.49 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.49 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.425 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.722 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.553 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.522 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.563 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.627 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.647 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.567 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.476 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m . . . . . 0 CA--C 1.519 -0.235 0 CA-C-O 120.744 0.307 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 14.4 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.862 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.862 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.424 HG23 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.424 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.628 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.406 0.146 . . . . 0.0 111.305 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.695 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.722 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.653 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.628 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 21' ' ' PRO . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.434 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.434 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.722 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.695 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.411 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.612 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.733 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.409 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.409 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.733 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.612 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.68 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.581 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.581 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.68 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.484 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.651 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.404 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.404 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.455 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.651 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.62 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m . . . . . 0 N--CA 1.454 -0.258 0 CA-C-O 120.685 0.278 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.692 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.863 HD13 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' HD1' HD22 ' A' ' 9' ' ' LEU . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.683 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.675 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.406 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.49 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.675 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.549 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.603 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.549 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.485 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.55 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.523 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.59 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.697 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.47 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.528 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.47 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.697 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.468 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.59 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.802 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -130.67 36.71 3.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.635 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.583 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.613 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.688 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.433 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.552 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.552 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.472 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.688 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.477 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.613 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.8 0 N-CA-C 112.225 -0.35 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t -84.5 -22.28 30.28 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.742 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.414 ' HA ' ' HD2' ' A' ' 25' ' ' PRO . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.742 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.584 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.97 43.89 2.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.402 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.744 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.52 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.744 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.686 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.007 -0.437 . . . . 0.0 112.007 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t -111.88 23.77 13.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.525 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.814 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.429 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.814 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.42 ' HA ' ' H ' ' A' ' 2' ' ' CYS . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.611 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.787 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t -106.97 22.41 16.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 9' ' ' LEU . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.619 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.634 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.514 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.716 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.716 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.442 ' HA ' ' H ' ' A' ' 2' ' ' CYS . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER -114.5 27.73 9.25 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.671 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.418 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.463 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.575 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.756 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.415 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.415 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.549 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.549 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.607 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.756 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.671 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.575 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -119.95 34.57 5.16 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.482 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.627 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.41 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.627 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.065 0 N-CA-C 112.68 -0.168 . . . . 0.0 112.68 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.868 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p -120.67 21.89 11.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.446 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.868 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.45 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.669 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.45 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.669 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.647 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.66 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.508 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.508 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.66 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.446 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.647 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.926 0 N-CA-C 111.841 -0.503 . . . . 0.0 111.841 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -114.71 23.14 12.92 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.606 ' HG2' ' HA ' ' A' ' 32' ' ' SER . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.565 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.534 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.514 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.481 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.514 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.534 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.606 ' HA ' ' HG2' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.454 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 112.061 -0.416 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t -117.84 15.14 14.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.554 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.704 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.704 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.671 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m -82.65 -15.69 51.08 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 -179.334 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.769 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.769 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.614 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.818 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.818 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.688 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.985 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t -130.67 -1.72 4.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.755 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.755 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.55 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.423 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.518 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.423 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.636 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.458 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.874 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p -118.82 39.02 3.62 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.683 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.494 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.722 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.553 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.49 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.49 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.425 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.722 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.553 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.522 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.997 0 N-CA-C 112.092 -0.403 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t -100.83 -10.84 20.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.563 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.627 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.647 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.567 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.476 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 32' ' ' SER . . . . . . . . 0 N--CA 1.486 1.993 0 N-CA-C 112.229 -0.348 . . . . 0.0 112.229 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m -123.47 26.01 8.03 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 122.583 -0.363 . . . . 0.0 111.154 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 14.4 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.862 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.862 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.424 HG23 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.424 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.515 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.35 -0.3 . . . . 0.0 112.35 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.628 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t -86.3 -20.53 28.23 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 122.789 -0.242 . . . . 0.0 111.305 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.695 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.722 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.653 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.628 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 21' ' ' PRO . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.434 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.434 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.722 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.695 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t -106.93 29.24 7.22 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.411 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.612 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.733 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.409 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.409 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.733 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.612 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.856 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.68 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER -118.5 43.83 2.4 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 179.311 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.581 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.581 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.68 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.466 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.651 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.404 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.404 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.455 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.651 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.62 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 32' ' ' SER . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m -113.81 29.73 7.78 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.641 -0.329 . . . . 0.0 110.785 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.692 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.863 HD13 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' HD1' HD22 ' A' ' 9' ' ' LEU . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.683 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.675 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.406 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.49 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.675 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.111 0 N-CA-C 112.333 -0.307 . . . . 0.0 112.333 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.549 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p -122.84 -17.53 6.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.603 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.549 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.485 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.55 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.523 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.59 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.697 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.47 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.528 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.47 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.697 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.468 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.59 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.635 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.583 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.613 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.688 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.433 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.552 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.552 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.472 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.688 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.477 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.613 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.742 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.414 ' HA ' ' HD2' ' A' ' 25' ' ' PRO . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.742 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.584 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.454 -0.241 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.402 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.744 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.52 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.744 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.686 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.525 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.814 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.429 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.814 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.611 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 9' ' ' LEU . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.619 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.634 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.514 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.716 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.716 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.671 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.418 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.463 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.575 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.756 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.415 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.415 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.549 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.549 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.607 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.756 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.671 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.575 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.454 -0.238 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.482 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.627 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.41 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.627 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.868 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p . . . . . 0 N--CA 1.455 -0.194 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.446 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.868 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.45 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.669 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.45 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.669 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.647 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.66 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.508 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.508 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.66 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.446 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.647 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.606 ' HG2' ' HA ' ' A' ' 32' ' ' SER . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.565 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.534 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.514 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.481 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.514 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.534 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.606 ' HA ' ' HG2' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.454 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.554 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.704 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.704 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.671 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.769 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.769 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.614 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.818 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.818 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.688 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t . . . . . 0 N--CA 1.457 -0.099 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.755 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.755 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.55 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.423 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.518 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.423 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.636 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.458 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.683 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.494 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.722 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.553 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.49 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.49 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.425 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.722 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.553 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.522 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.454 HE21 ' HB2' ' A' ' 6' ' ' GLN . 5.9 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.563 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.627 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.647 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.567 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.476 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m . . . . . 0 CA--C 1.519 -0.235 0 CA-C-O 120.744 0.307 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.862 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.862 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.424 HG23 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.424 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.628 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.406 0.146 . . . . 0.0 111.305 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.695 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.722 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.653 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.628 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 21' ' ' PRO . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.434 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.434 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.722 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.695 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.411 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.612 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.733 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.409 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.409 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.733 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.612 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.68 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER . . . . . 0 N--CA 1.453 -0.284 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.581 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.581 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.68 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.484 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.651 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.404 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.404 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.455 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.651 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.62 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m . . . . . 0 N--CA 1.454 -0.258 0 CA-C-O 120.685 0.278 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.692 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.863 HD13 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' HD1' HD22 ' A' ' 9' ' ' LEU . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.683 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.675 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.406 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.49 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.675 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.549 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.603 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.549 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.485 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.55 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.523 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.59 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.697 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.47 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.528 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.47 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.697 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.468 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.59 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.802 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -130.67 36.71 3.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.0 0.429 . . . . 0.0 110.853 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HB3' ' N ' ' A' ' 32' ' ' SER . 1.2 pm0 -80.45 169.99 16.97 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.167 0.508 . . . . 0.0 110.869 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.27 36.7 79.55 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.621 -0.718 . . . . 0.0 112.102 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 29.5 mmtm -131.01 170.16 14.86 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 23.8 tt0 -106.08 131.62 53.13 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.7 p -113.15 -176.4 2.89 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.711 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 103.59 -124.18 8.02 Favored Glycine 0 N--CA 1.445 -0.707 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.635 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.7 OUTLIER -74.54 -53.49 9.33 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.08 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.583 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.1 OUTLIER -94.72 61.1 2.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.452 0.644 . . . . 0.0 109.859 179.04 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 9.9 ptt-85 -69.92 116.9 10.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.398 -0.819 . . . . 0.0 111.574 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.4 28.54 4.94 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.067 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.0 p -143.49 155.87 44.46 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.019 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -157.82 147.96 16.7 Favored Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.21 -102.72 1.3 Allowed Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.016 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -131.88 82.58 0.31 Allowed Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.1 m -134.37 141.24 46.81 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.963 0.411 . . . . 0.0 109.925 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.613 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.91 128.28 33.89 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.89 179.67 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 43.9 t -96.84 96.52 8.61 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.688 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 85.7 m95 -93.57 115.48 65.13 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.783 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -59.31 150.27 75.69 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 123.069 2.513 . . . . 0.0 113.061 -178.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.433 HG23 ' HA2' ' A' ' 28' ' ' GLY . 35.2 p -110.37 -147.43 0.42 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.744 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.4 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.6 t -80.29 -21.72 11.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.064 0.459 . . . . 0.0 110.978 -179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.552 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.3 OUTLIER -98.05 124.62 46.87 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.963 -179.637 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.77 113.14 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.85 2.367 . . . . 0.0 111.959 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.57 -6.84 49.57 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.552 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 95.7 t -110.24 134.26 52.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -153.14 -172.51 21.5 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.632 -0.794 . . . . 0.0 111.784 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -127.94 138.32 55.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-O 121.455 0.645 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.472 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 3.7 m -80.74 130.36 35.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.733 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.688 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -97.97 -179.63 4.47 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.801 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.477 ' N ' ' HB3' ' A' ' 3' ' ' GLU . 15.6 m -48.78 -48.14 41.32 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.613 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 45.3 m . . . . . 0 C--O 1.245 0.823 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 -179.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.8 0 N-CA-C 112.225 -0.35 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 47.4 t -84.5 -22.28 30.28 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.899 0.38 . . . . 0.0 111.155 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -69.65 166.18 19.63 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-O 121.326 0.584 . . . . 0.0 111.124 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.51 36.39 58.95 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.219 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.91 170.58 13.75 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.3 tp60 -101.66 140.84 35.4 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 31.2 p -127.59 -169.91 2.13 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.08 -105.87 2.4 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 92.1 mt -70.72 -74.62 0.14 Allowed 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.85 68.36 9.31 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.289 0.566 . . . . 0.0 110.057 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.8 ptt-85 -71.04 116.22 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.101 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.49 31.9 5.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.327 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 25.1 p -146.15 167.56 23.14 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.221 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.32 144.41 8.82 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.615 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 -129.47 6.53 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.017 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -105.56 29.64 11.1 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.02 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.5 m -89.33 141.79 28.23 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.949 0.405 . . . . 0.0 109.964 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.7 OUTLIER -83.74 149.99 26.1 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.958 -178.862 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.2 t -110.15 93.61 4.58 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.742 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -91.25 115.37 64.26 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.097 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.75 149.29 88.62 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 123.118 2.546 . . . . 0.0 112.828 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 72.6 p -106.42 -152.21 0.47 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.529 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 3.9 t -80.38 -19.03 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.143 0.496 . . . . 0.0 110.944 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.414 ' HA ' ' HD2' ' A' ' 25' ' ' PRO . 1.3 m -99.53 124.24 45.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.935 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 14.9 Cg_endo -57.95 114.97 2.2 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 123.022 2.481 . . . . 0.0 112.237 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.52 -12.5 54.28 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.934 -0.65 . . . . 0.0 111.517 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 60.8 t -103.43 129.26 55.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.512 -0.344 . . . . 0.0 110.076 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.06 177.57 24.34 Favored Glycine 0 N--CA 1.439 -1.148 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.6 tt -126.53 137.21 58.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 121.677 0.751 . . . . 0.0 111.606 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.0 m -80.94 135.71 35.93 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.711 179.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.742 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -109.07 175.06 5.59 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.441 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.8 m -53.72 -41.12 66.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.43 0.633 . . . . 0.0 111.508 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.584 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.5 m . . . . . 0 C--O 1.246 0.902 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.387 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.97 43.89 2.19 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.204 0.526 . . . . 0.0 110.109 179.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -73.56 160.6 31.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.705 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.46 41.25 25.76 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.939 -0.648 . . . . 0.0 113.536 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -139.9 175.68 9.38 Favored 'General case' 0 CA--C 1.512 -0.51 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 177.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 0.8 OUTLIER -108.54 143.78 37.09 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.183 -179.043 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 29.5 p -127.84 -173.81 3.03 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.37 -105.46 2.6 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.174 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.1 tp -73.14 -72.45 0.25 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.63 63.86 7.77 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.346 0.594 . . . . 0.0 109.678 179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 8.3 ptt180 -70.01 113.08 6.87 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.752 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -99.2 13.18 33.9 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.522 179.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.402 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 23.3 p -137.05 157.34 46.93 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.416 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -119.4 -144.33 7.3 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.56 -0.828 . . . . 0.0 111.908 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.3 118.74 6.38 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.495 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 131.46 2.99 4.36 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.839 -0.696 . . . . 0.0 111.553 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.402 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -134.26 144.71 48.54 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.186 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.0 140.06 34.17 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.751 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 53.9 t -106.17 99.52 9.1 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.744 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -100.04 114.23 65.58 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.967 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_exo -61.4 148.36 93.15 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.898 2.399 . . . . 0.0 112.644 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 52.9 p -107.08 -153.99 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.668 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.6 t -79.16 -26.21 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.053 0.454 . . . . 0.0 110.974 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.52 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 0.2 OUTLIER -89.31 123.98 65.7 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.83 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.41 116.22 3.09 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.96 2.44 . . . . 0.0 112.275 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.94 -6.24 58.36 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.642 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.52 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 51.8 t -107.71 130.32 60.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-O 120.808 0.337 . . . . 0.0 110.356 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.58 172.82 27.02 Favored Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -121.76 138.6 51.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 121.449 0.642 . . . . 0.0 111.47 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 8.0 m -80.98 133.55 35.53 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.297 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.744 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.0 OUTLIER -106.47 -166.1 1.15 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.771 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -54.72 -60.83 2.83 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.686 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 39.6 m . . . . . 0 C--O 1.247 0.936 0 CA-C-O 119.115 -0.469 . . . . 0.0 109.893 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.007 -0.437 . . . . 0.0 112.007 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 10.9 t -111.88 23.77 13.43 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.234 0.54 . . . . 0.0 110.582 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -77.9 167.46 21.46 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.517 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.43 33.33 61.38 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.671 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 28.8 mmtm -130.08 167.88 17.63 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 28' ' ' GLY . 0.3 OUTLIER -121.45 136.27 54.97 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.924 0.392 . . . . 0.0 110.798 -179.344 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -113.89 167.83 10.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 93.43 110.01 2.02 Favored Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.0 mt 69.32 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.819 0.447 . . . . 0.0 110.097 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.66 79.47 2.25 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.284 0.564 . . . . 0.0 110.112 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -73.27 123.09 23.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.137 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.44 14.32 32.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.177 0.513 . . . . 0.0 110.81 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.525 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -124.62 171.14 10.28 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.562 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.43 -160.65 36.74 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.701 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.68 -19.57 63.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.598 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -98.06 54.08 1.19 Allowed Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.018 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.5 m -145.87 141.9 28.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.1 OUTLIER -81.86 139.55 34.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.345 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -107.79 100.26 9.65 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.814 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 92.0 m95 -98.36 116.77 65.42 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.724 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -56.68 149.52 58.58 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 123.093 2.529 . . . . 0.0 113.127 -178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.429 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.8 p -110.09 -149.6 0.44 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.641 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.36 -22.36 11.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.266 0.555 . . . . 0.0 111.194 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.546 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.8 122.43 58.68 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.947 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 17.0 Cg_endo -58.36 109.75 0.55 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.912 2.408 . . . . 0.0 112.051 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.65 -13.33 32.64 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.512 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.546 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 91.2 t -103.83 134.55 44.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 6' ' ' GLN . . . -149.55 172.14 29.58 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -115.11 138.02 46.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.536 0.684 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.774 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 16.8 m -81.3 133.7 35.47 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.333 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.814 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -107.68 -167.94 1.32 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.464 -179.379 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.42 ' HA ' ' H ' ' A' ' 2' ' ' CYS . 4.5 m -49.38 -68.39 0.18 Allowed 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.611 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 38.6 m . . . . . 0 C--O 1.244 0.807 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.819 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.787 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.9 t -106.97 22.41 16.02 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.991 0.424 . . . . 0.0 110.975 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 7.2 mp0 -80.23 175.36 10.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.73 23.75 75.96 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.21 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -134.15 163.9 28.56 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.525 ' HG3' ' HD1' ' A' ' 10' ' ' PHE . 2.9 pt20 -110.7 153.35 25.39 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.0 p -121.07 -173.14 2.54 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.919 -179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 96.61 -128.62 9.61 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 9' ' ' LEU . 5.2 mp -70.2 -38.1 75.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.313 0.578 . . . . 0.0 110.068 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.525 ' HD1' ' HG3' ' A' ' 6' ' ' GLN . 0.2 OUTLIER -107.84 55.62 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.995 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.619 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 1.0 OUTLIER -69.5 113.84 7.17 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.46 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.28 -0.75 52.59 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.342 0.591 . . . . 0.0 110.377 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.634 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 6.1 p -112.95 -175.57 2.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.54 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -116.99 -161.47 12.26 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.225 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.13 -18.89 79.42 Favored Glycine 0 C--O 1.235 0.166 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.43 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.2 27.46 6.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.997 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.3 m -140.53 139.66 35.09 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.514 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.59 139.78 33.61 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.875 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.1 t -104.19 99.06 8.78 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.57 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.716 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.7 m95 -97.05 114.03 64.0 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.858 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -59.38 150.49 74.64 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 123.297 2.665 . . . . 0.0 113.101 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 54.9 p -108.71 -150.68 0.46 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.595 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.2 t -80.3 -19.39 12.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.112 0.482 . . . . 0.0 110.975 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.419 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -99.7 122.63 50.56 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.849 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.51 111.19 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.966 2.444 . . . . 0.0 111.955 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.71 -10.64 35.17 Favored Glycine 0 N--CA 1.45 -0.396 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 63.3 t -106.48 131.5 56.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.9 172.42 31.93 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 3.6 tt -119.74 141.51 39.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.594 0.711 . . . . 0.0 111.449 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.514 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 18.9 m -81.08 135.33 35.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.458 -1.246 . . . . 0.0 110.063 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.716 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.37 -176.07 2.98 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.944 -179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.442 ' HA ' ' H ' ' A' ' 2' ' ' CYS . 6.2 m -49.94 -49.88 48.52 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.1 m . . . . . 0 C--O 1.246 0.87 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.607 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.3 OUTLIER -114.5 27.73 9.25 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.88 0.371 . . . . 0.0 110.502 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.671 ' CG ' ' HA ' ' A' ' 32' ' ' SER . 3.3 mp0 -71.74 145.61 48.67 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.191 -179.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.26 44.14 94.16 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.491 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.418 ' O ' HG13 ' A' ' 29' ' ' ILE . 32.3 mmtm -128.56 169.49 14.32 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.463 ' O ' ' HB3' ' A' ' 11' ' ' ARG . 26.5 tt0 -107.58 132.76 52.93 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.69 -178.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.0 p -130.14 163.23 27.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.482 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.45 113.28 2.17 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.868 179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 mp 55.86 -96.53 0.06 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.367 0.667 . . . . 0.0 112.46 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -77.37 -4.35 44.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.508 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 6' ' ' GLN . 25.4 mmt180 -106.42 99.93 9.48 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.463 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 m -81.2 145.7 30.86 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.356 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.4 t -148.78 171.57 16.04 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.05 23.12 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.132 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.95 -7.67 62.7 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 121.129 -0.557 . . . . 0.0 113.148 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.1 -27.49 60.02 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.849 -0.691 . . . . 0.0 111.966 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 31' ' ' SER . 34.5 m -101.62 148.45 25.22 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.099 0.476 . . . . 0.0 110.237 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.575 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.09 139.27 34.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.553 -179.376 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 34.7 t -100.51 93.17 5.48 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.756 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.3 m95 -91.04 122.22 66.87 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.011 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.17 149.37 64.05 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.03 2.487 . . . . 0.0 112.98 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.415 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 47.4 p -108.19 -150.5 0.45 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.817 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.415 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.8 m -80.47 -19.49 11.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.008 0.433 . . . . 0.0 111.593 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.549 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.5 OUTLIER -96.18 122.68 57.34 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.522 -179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.26 108.39 0.39 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.877 2.385 . . . . 0.0 112.125 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.32 -11.97 33.58 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.581 -0.607 . . . . 0.0 111.581 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.549 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 87.4 t -104.39 132.83 50.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.584 -0.308 . . . . 0.0 110.39 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -141.98 176.77 21.86 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.304 -0.719 . . . . 0.0 111.304 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 5' ' ' LYS . 3.2 tt -129.03 139.47 51.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.597 0.713 . . . . 0.0 111.094 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.607 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.0 m -80.18 131.36 35.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.816 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.756 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -94.48 -172.36 2.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.548 -178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.671 ' HA ' ' CG ' ' A' ' 3' ' ' GLU . 10.3 m -63.42 -39.08 93.54 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.434 0.635 . . . . 0.0 110.965 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.575 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 17.1 m . . . . . 0 C--O 1.246 0.905 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -119.95 34.57 5.16 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.148 0.499 . . . . 0.0 110.445 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 28.6 mp0 -74.14 160.99 30.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.59 36.85 84.17 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.802 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 28.1 mmtm -129.05 169.14 15.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 10.8 mt-30 -102.33 143.06 32.56 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.8 p -117.33 -172.86 2.3 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 84.26 -116.96 4.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.513 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.1 tt -75.28 -58.18 3.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.482 ' HD1' ' HB3' ' A' ' 6' ' ' GLN . 0.3 OUTLIER -86.48 55.99 3.8 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.048 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 19.6 ptt-85 -70.97 116.04 10.8 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.599 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.05 28.26 8.44 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.84 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 7.5 p -139.4 171.13 14.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.065 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -92.21 -170.86 41.27 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.24 10.87 46.76 Favored Glycine 0 C--O 1.228 -0.249 0 C-N-CA 121.022 -0.608 . . . . 0.0 112.634 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -111.35 18.87 25.08 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.191 -0.763 . . . . 0.0 111.191 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 13' ' ' CYS . 1.4 m -128.52 143.89 51.05 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.627 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.24 153.5 25.88 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.982 0.42 . . . . 0.0 111.102 -179.208 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -105.17 90.23 3.37 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -89.39 110.07 36.08 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.043 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.29 147.91 92.04 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.994 2.463 . . . . 0.0 112.849 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 71.7 p -105.7 -154.39 0.51 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.586 -0.733 . . . . 0.0 110.521 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.3 t -80.27 -21.08 11.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 121.047 0.451 . . . . 0.0 111.059 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.41 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.2 m -95.26 121.68 61.5 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.87 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -57.9 109.51 0.5 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.868 2.379 . . . . 0.0 111.997 179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.92 -12.3 29.46 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 61.9 t -104.53 130.13 55.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.905 0.383 . . . . 0.0 110.123 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -145.81 167.36 27.7 Favored Glycine 0 N--CA 1.438 -1.216 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 1.9 tt -122.31 141.01 44.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-O 121.575 0.702 . . . . 0.0 111.54 -179.338 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 30.7 m -81.18 137.49 35.89 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.552 -1.203 . . . . 0.0 110.302 179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -107.56 -171.27 1.84 Allowed 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.078 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.4 m -61.28 -43.2 99.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.178 0.513 . . . . 0.0 110.707 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.627 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.9 m . . . . . 0 C--O 1.246 0.908 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.065 0 N-CA-C 112.68 -0.168 . . . . 0.0 112.68 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.868 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 1.2 p -120.67 21.89 11.36 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.209 0.528 . . . . 0.0 110.449 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.446 ' OE2' ' HA ' ' A' ' 32' ' ' SER . 24.8 mp0 -76.43 159.49 30.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.216 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.48 31.28 79.74 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.209 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.868 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 10.7 mttm -128.11 166.5 18.34 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.45 ' HG2' ' HE1' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -96.56 146.65 24.63 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.368 0.604 . . . . 0.0 111.767 -178.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.669 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 28.7 p -130.12 -165.3 1.52 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.521 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.12 -96.52 1.1 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.609 -0.805 . . . . 0.0 111.465 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 79.5 mt -73.77 -83.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.45 ' HE1' ' HG2' ' A' ' 6' ' ' GLN . 0.1 OUTLIER -84.53 67.03 9.8 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.43 0.634 . . . . 0.0 109.564 179.206 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.669 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 4.4 ptp180 -70.58 118.26 13.15 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.612 -178.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.01 21.72 17.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.453 0.644 . . . . 0.0 109.648 178.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 1.7 m -138.22 165.83 25.69 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.394 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.49 -172.18 30.75 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.24 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.55 -6.57 62.69 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.115 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -77.01 -16.23 80.96 Favored Glycine 0 C--O 1.226 -0.389 0 C-N-CA 120.98 -0.629 . . . . 0.0 111.789 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.464 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.4 m -108.87 146.08 34.29 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.647 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.03 140.38 33.95 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.846 0.355 . . . . 0.0 110.95 -178.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.0 95.91 6.45 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.583 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.66 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 90.2 m95 -93.9 112.06 55.51 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.838 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.24 150.38 80.12 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.253 2.635 . . . . 0.0 113.202 -178.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 58.2 p -108.28 -150.84 0.46 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.502 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -80.24 -21.37 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.294 0.568 . . . . 0.0 111.146 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.508 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -95.54 122.57 58.82 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.79 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_endo -58.37 111.62 0.93 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.902 2.401 . . . . 0.0 112.07 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.97 -15.15 37.2 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.469 -0.653 . . . . 0.0 111.469 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.508 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 86.4 t -100.57 129.3 51.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.916 0.388 . . . . 0.0 110.18 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.69 170.56 29.84 Favored Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.2 tt -118.99 140.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.457 0.646 . . . . 0.0 111.458 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 34.8 m -80.4 138.6 36.66 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.885 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.66 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.4 m -107.18 173.79 6.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.063 -0.972 . . . . 0.0 109.688 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.446 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 7.1 m -53.29 -42.5 66.66 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.647 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 18.0 m . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.926 0 N-CA-C 111.841 -0.503 . . . . 0.0 111.841 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -114.71 23.14 12.92 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.963 0.411 . . . . 0.0 110.626 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.606 ' HG2' ' HA ' ' A' ' 32' ' ' SER . 2.1 mp0 -72.96 146.38 46.07 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.667 -178.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.82 43.41 94.01 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.58 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 32.8 mmtm -131.91 167.77 19.02 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 -102.83 129.06 49.38 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.068 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.23 -92.5 0.5 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.517 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.65 -164.63 48.61 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 -178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.565 ' H ' HD22 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -94.85 38.42 1.12 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.153 0.501 . . . . 0.0 110.429 179.442 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HD2' ' HG3' ' A' ' 11' ' ' ARG . 16.8 p90 -145.32 -23.84 0.48 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.518 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HG3' ' HD2' ' A' ' 10' ' ' PHE . 97.7 mtt180 -130.18 135.55 48.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.919 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.7 m -111.82 104.08 12.37 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.058 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.3 p -84.3 -26.28 28.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.684 0.754 . . . . 0.0 110.933 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 146.38 172.07 16.35 Favored Glycine 0 C--N 1.306 -1.121 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.319 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -98.5 -7.75 55.44 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.204 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.35 -27.02 64.49 Favored Glycine 0 C--O 1.227 -0.318 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.705 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.534 ' HB3' ' O ' ' A' ' 31' ' ' SER . 11.2 m -108.29 143.52 37.04 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.606 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.78 142.96 31.18 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.855 -178.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 16.9 t -93.56 93.58 8.16 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 179.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 84.9 m95 -87.82 119.72 70.64 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.056 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -58.96 147.89 87.59 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.974 2.449 . . . . 0.0 112.828 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.9 p -107.64 -152.5 0.48 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 t -78.49 -25.87 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.083 0.468 . . . . 0.0 111.004 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.514 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -90.01 121.32 68.93 Favored Pre-proline 0 C--N 1.321 -0.653 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.698 -179.851 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -57.71 106.42 0.25 Allowed 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 123.017 2.478 . . . . 0.0 112.148 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.481 ' HA2' HD11 ' A' ' 9' ' ' LEU . . . 113.76 -17.12 20.71 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.544 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.514 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.9 t -98.1 135.61 32.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.59 167.78 29.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -125.13 141.2 45.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.399 0.619 . . . . 0.0 110.683 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.606 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 2.7 m -80.43 129.8 34.75 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.025 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.534 ' O ' ' HB3' ' A' ' 17' ' ' CYS . 2.3 p -89.42 -169.56 2.53 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.443 -179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.606 ' HA ' ' HG2' ' A' ' 3' ' ' GLU . 14.3 m -66.46 -36.93 84.0 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.547 0.689 . . . . 0.0 110.589 179.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.454 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 16.0 m . . . . . 0 C--O 1.252 1.215 0 CA-C-O 117.375 -1.298 . . . . 0.0 108.377 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 112.061 -0.416 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.557 ' HB3' ' O ' ' A' ' 31' ' ' SER . 6.4 t -117.84 15.14 14.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.369 0.604 . . . . 0.0 109.986 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.468 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 4.3 mp0 -80.1 169.54 17.69 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.078 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.89 15.19 81.06 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.894 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 31.7 mmtp -110.48 165.95 11.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.93 0.395 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.554 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 1.5 tp60 -117.31 139.36 50.93 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.7 p -130.75 171.77 12.73 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.315 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.59 -113.04 1.8 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.704 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -70.68 -22.69 62.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.575 0.702 . . . . 0.0 109.464 178.465 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.704 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 24.5 p90 -146.34 144.14 29.58 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 12.4 ptm85 -131.1 138.07 49.36 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.082 -0.647 . . . . 0.0 112.016 -179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -111.79 23.12 14.2 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.961 0.886 . . . . 0.0 109.222 178.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -136.43 159.82 40.62 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.583 -178.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.89 -169.8 43.47 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.256 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.98 -14.11 80.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.489 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -88.77 28.94 6.1 Favored Glycine 0 C--O 1.225 -0.453 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.079 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.6 m -134.78 141.33 46.42 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.7 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -81.26 140.36 34.92 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 -178.796 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 48.4 t -102.63 97.76 7.91 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.671 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 87.2 m95 -94.94 114.28 63.27 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.691 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.56 150.94 49.07 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 123.289 2.66 . . . . 0.0 113.388 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -109.67 -152.78 0.5 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.646 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.1 p -80.56 -22.21 11.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.296 0.57 . . . . 0.0 111.086 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.539 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.4 m -93.19 122.02 64.19 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.921 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 31.3 Cg_exo -59.46 109.55 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.899 2.4 . . . . 0.0 111.846 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.47 -5.78 33.48 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.793 -0.717 . . . . 0.0 111.405 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.539 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 88.1 t -112.14 131.34 63.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.758 0.313 . . . . 0.0 110.198 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.89 173.05 25.54 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.2 tt -125.62 137.61 57.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-O 121.33 0.586 . . . . 0.0 110.658 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 19.8 m -81.5 147.02 29.89 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.046 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.1 m -110.72 -176.78 3.06 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.451 -1.25 . . . . 0.0 110.33 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.6 m -53.44 -43.28 67.91 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 21.7 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.389 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 112.423 -0.271 . . . . 0.0 112.423 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 31' ' ' SER . 62.2 m -82.65 -15.69 51.08 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.603 0.24 . . . . 0.0 111.203 -179.334 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.6 mp0 -57.3 156.81 7.08 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.166 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.14 85.87 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.656 -0.702 . . . . 0.0 113.334 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.3 mtmm -124.27 168.13 13.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 117.328 0.564 . . . . 0.0 110.595 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -100.02 148.79 24.14 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.607 -178.278 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.769 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 32.1 p -130.18 -166.95 1.74 Allowed 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.271 178.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.65 -105.08 1.43 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.605 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -68.13 -67.06 0.49 Allowed 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.181 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -89.45 60.86 5.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.769 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.5 ptt-85 -68.9 98.19 0.92 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.392 -178.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.6 m -108.5 34.12 3.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.073 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 13.1 m -137.05 143.48 42.68 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.696 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -141.39 136.31 7.37 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 131.06 -134.19 7.61 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.741 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -110.63 39.53 2.86 Favored Glycine 0 C--O 1.225 -0.467 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.649 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 145.8 24.98 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.827 0.346 . . . . 0.0 110.298 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.614 ' HD3' ' O ' ' A' ' 33' ' ' SER . 0.3 OUTLIER -82.28 158.15 23.58 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.811 -179.163 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.17 95.47 4.56 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.818 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 95.3 m95 -96.41 113.58 62.77 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.298 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -61.16 147.72 94.85 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 123.007 2.471 . . . . 0.0 112.57 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -105.0 -153.74 0.49 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.515 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.4 m -79.29 -18.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 111.709 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -100.22 122.62 49.59 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.826 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.39 112.18 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 123.144 2.563 . . . . 0.0 112.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 108.62 -17.23 33.56 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.568 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 43.1 t -98.51 128.83 49.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.48 164.33 29.04 Favored Glycine 0 N--CA 1.439 -1.108 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.5 tt -113.83 140.43 34.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.638 0.732 . . . . 0.0 111.415 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 60.0 m -80.57 140.19 35.91 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 114.566 -1.197 . . . . 0.0 111.194 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.818 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.9 OUTLIER -118.89 172.83 7.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.646 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.6 m -57.15 -46.56 82.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.948 0.404 . . . . 0.0 111.835 -179.264 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.688 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 29.6 m . . . . . 0 C--O 1.247 0.934 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.985 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 11.4 t -130.67 -1.72 4.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.064 0.459 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.0 pm0 -80.49 172.95 13.1 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.016 0.436 . . . . 0.0 110.71 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.39 28.66 63.31 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.619 -0.8 . . . . 0.0 111.472 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 12' ' ' SER . 27.5 mmtm -128.53 166.93 17.86 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 43.7 tt0 -106.17 139.05 41.29 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.755 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 21.1 p -117.6 -166.73 1.23 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.462 179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.75 -112.03 4.3 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 28.3 tp -68.78 -62.08 1.53 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.102 0.477 . . . . 0.0 110.202 179.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.68 72.19 0.89 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.866 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.755 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 9.8 ptt180 -69.95 119.53 14.3 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.255 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.55 ' HB2' ' HB3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -80.34 -11.62 59.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.291 179.476 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.39 122.7 29.31 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.685 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -114.59 -1.85 22.91 Favored Glycine 0 CA--C 1.503 -0.661 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.111 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -106.14 -157.31 21.9 Favored Glycine 0 C--N 1.304 -1.204 0 CA-C-N 114.734 -0.733 . . . . 0.0 111.999 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.33 42.95 2.64 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.064 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -89.79 147.57 23.73 Favored 'General case' 0 C--N 1.321 -0.657 0 C-N-CA 123.058 0.543 . . . . 0.0 110.153 -179.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.5 167.84 17.03 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.4 -179.466 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 44.5 t -122.04 81.35 1.82 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 99.4 m95 -79.37 112.71 30.69 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.116 -178.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -61.29 149.15 90.74 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.134 2.556 . . . . 0.0 113.171 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.423 HG23 ' HA2' ' A' ' 28' ' ' GLY . 69.1 p -108.4 -151.65 0.47 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.42 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.2 p -80.34 -20.75 11.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.256 0.551 . . . . 0.0 111.159 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.518 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.3 m -97.56 122.98 53.8 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.996 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.25 112.69 1.31 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.883 2.388 . . . . 0.0 111.844 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.85 -10.86 41.28 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.377 -0.689 . . . . 0.0 111.377 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 89.1 t -106.68 131.4 56.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.314 -0.443 . . . . 0.0 109.922 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.423 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -149.99 178.57 27.39 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 111.301 -0.719 . . . . 0.0 111.301 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -124.32 141.12 45.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.559 0.695 . . . . 0.0 111.198 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.636 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 54.0 m -80.53 142.72 33.88 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.06 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.8 m -144.24 150.8 38.51 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.6 m -64.22 -8.91 14.15 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -178.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.458 ' HA ' HH21 ' A' ' 18' ' ' ARG . 47.6 m . . . . . 0 C--N 1.304 -1.401 0 CA-C-O 118.321 -0.847 . . . . 0.0 109.906 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.874 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 5.0 p -118.82 39.02 3.62 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.305 0.574 . . . . 0.0 109.959 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.2 mp0 -65.92 168.54 7.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.103 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.9 42.04 17.41 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.756 179.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.683 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 27.5 mmtm -132.06 166.66 21.23 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.494 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 40.8 tt0 -141.96 147.14 36.49 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 120.81 0.338 . . . . 0.0 110.982 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.7 p -107.99 -52.81 2.71 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.367 0.603 . . . . 0.0 110.105 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -56.75 131.89 51.78 Favored Glycine 0 C--N 1.318 -0.432 0 CA-C-N 114.778 -1.101 . . . . 0.0 112.331 179.02 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 87.9 mt 71.18 -85.99 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 123.159 0.583 . . . . 0.0 110.071 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -93.46 90.23 6.62 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 7.1 ptm180 -70.53 67.18 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.456 -178.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.1 m -102.21 75.61 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 10.7 t -146.96 169.18 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.488 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.49 158.66 14.16 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 121.037 -0.602 . . . . 0.0 111.654 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.2 85.09 0.81 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.314 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 174.44 -30.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.214 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.722 ' HB2' ' HB3' ' A' ' 30' ' ' CYS . 1.3 m -88.66 141.49 28.47 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.14 0.495 . . . . 0.0 110.317 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 33' ' ' SER . 0.2 OUTLIER -82.62 112.68 19.73 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.317 -179.506 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.8 t -84.22 105.9 15.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 179.042 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.553 ' HD1' ' OG ' ' A' ' 31' ' ' SER . 87.1 m95 -95.58 126.91 43.67 Favored Pre-proline 0 C--N 1.32 -0.713 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.881 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 33.2 Cg_exo -58.54 148.55 80.72 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.934 2.423 . . . . 0.0 112.611 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.49 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 1.4 p -108.92 -151.76 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.125 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.49 ' H ' ' HB ' ' A' ' 22' ' ' THR . 10.3 t -73.76 -27.68 23.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.953 0.406 . . . . 0.0 111.705 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.425 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.1 m -89.73 120.32 69.47 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.653 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -56.32 110.32 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.054 2.502 . . . . 0.0 112.192 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.52 -14.8 32.58 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.903 -0.665 . . . . 0.0 111.667 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 92.2 t -97.85 135.89 30.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HG3' ' A' ' 6' ' ' GLN . . . -154.7 153.53 24.87 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.449 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -117.41 142.5 31.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.422 0.629 . . . . 0.0 111.345 -178.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.722 ' HB3' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -79.35 139.36 37.79 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.846 -179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.553 ' OG ' ' HD1' ' A' ' 20' ' ' TRP . 2.6 m -98.65 -169.57 1.81 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.772 -178.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.0 m -53.21 -45.44 68.64 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.522 ' O ' ' HB2' ' A' ' 18' ' ' ARG . 23.2 m . . . . . 0 C--O 1.25 1.103 0 CA-C-O 117.266 -1.35 . . . . 0.0 107.776 -179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.997 0 N-CA-C 112.092 -0.403 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.567 ' HB3' ' O ' ' A' ' 31' ' ' SER . 48.4 t -100.83 -10.84 20.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.987 0.422 . . . . 0.0 109.947 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.658 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 2.4 mp0 -59.93 152.85 22.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.401 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 121.24 -20.93 8.33 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.361 -0.923 . . . . 0.0 113.169 179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.2 mppt? -114.07 173.87 6.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 117.125 0.463 . . . . 0.0 110.647 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.454 HE21 ' HB2' ' A' ' 6' ' ' GLN . 5.9 mt-30 -116.55 171.28 7.96 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.724 -178.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 1.4 p -121.96 -167.33 1.52 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.583 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.07 -122.84 7.09 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.293 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 24.0 mt -69.75 -45.34 68.32 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.348 0.594 . . . . 0.0 109.871 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.37 47.49 1.08 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.886 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.563 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 19.6 ptt180 -69.4 109.71 4.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.235 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -113.87 25.72 10.95 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.921 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.627 ' SG ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 m -137.7 159.1 42.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.657 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -105.41 -172.73 23.99 Favored Glycine 0 N--CA 1.445 -0.702 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 179.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.43 104.19 1.39 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.382 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.48 -44.85 0.25 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' O ' ' A' ' 31' ' ' SER . 1.6 m -89.66 142.3 27.81 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.647 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.8 OUTLIER -83.2 156.56 23.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.287 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 52.9 t -111.58 104.43 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -94.79 119.54 65.94 Favored Pre-proline 0 C--N 1.318 -0.799 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.212 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -58.66 144.32 97.83 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.839 2.359 . . . . 0.0 112.867 -178.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.4 p -99.62 -154.8 0.48 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.628 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.5 t -80.16 -20.54 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.178 0.513 . . . . 0.0 110.967 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.9 m -97.1 121.56 58.66 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.718 -179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -57.58 111.78 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.955 2.436 . . . . 0.0 112.004 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.43 -13.4 28.02 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.42 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 56.0 t -103.53 126.99 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 120.716 0.293 . . . . 0.0 110.318 179.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -144.36 149.24 21.29 Favored Glycine 0 N--CA 1.442 -0.905 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 4.2 tt -110.37 147.45 14.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.431 0.634 . . . . 0.0 111.899 -177.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.658 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 29.6 m -78.32 140.21 38.81 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.809 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.567 ' O ' ' HB3' ' A' ' 2' ' ' CYS . 2.7 p -105.15 -174.92 2.65 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.189 178.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 11.4 m -58.14 -40.52 81.55 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.271 0.558 . . . . 0.0 111.151 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.476 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 22.7 m . . . . . 0 C--O 1.246 0.891 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 32' ' ' SER . . . . . . . . 0 N--CA 1.486 1.993 0 N-CA-C 112.229 -0.348 . . . . 0.0 112.229 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 56.4 m -123.47 26.01 8.03 Favored 'General case' 0 C--N 1.324 -0.535 0 O-C-N 122.583 -0.363 . . . . 0.0 111.154 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -65.33 148.18 52.15 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.023 0.44 . . . . 0.0 110.017 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.76 0.55 68.95 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.558 -0.747 . . . . 0.0 113.191 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 78.9 mttt -103.16 166.97 10.12 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 117.315 0.558 . . . . 0.0 110.437 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -108.24 143.26 37.31 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.235 -177.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.862 ' HA ' ' HA ' ' A' ' 11' ' ' ARG . 15.8 p -121.74 -159.67 0.83 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.147 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.96 -130.88 10.4 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 9' ' ' LEU . 0.6 OUTLIER -71.34 -33.96 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.109 0.48 . . . . 0.0 109.881 179.223 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -106.83 49.61 0.8 Allowed 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.862 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 5.7 ptm180 -69.68 93.07 0.69 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.02 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -91.93 49.33 1.53 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.324 0.583 . . . . 0.0 109.968 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 23.1 m -138.49 170.66 15.61 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.066 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -90.62 -157.04 33.16 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.178 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -94.2 -12.34 56.37 Favored Glycine 0 C--O 1.227 -0.297 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.5 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -95.85 36.38 3.87 Favored Glycine 0 N--CA 1.45 -0.432 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 179.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.518 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -146.41 140.87 26.63 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.1 OUTLIER -82.59 163.49 21.42 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.24 0.543 . . . . 0.0 111.29 -179.079 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.5 t -118.76 88.19 2.88 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 177.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 80.4 m95 -84.91 111.14 33.36 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.149 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.9 150.09 87.56 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 123.39 2.727 . . . . 0.0 113.31 -177.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.424 HG23 ' HA2' ' A' ' 28' ' ' GLY . 57.7 p -107.49 -150.89 0.45 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.326 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.6 t -80.51 -18.74 12.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.105 0.478 . . . . 0.0 111.107 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 m -102.74 122.65 45.23 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -58.31 111.21 0.79 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 123.031 2.488 . . . . 0.0 111.909 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.73 -16.48 26.03 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 63.9 t -101.86 132.01 48.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.424 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -154.47 174.71 32.81 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.7 -0.762 . . . . 0.0 111.557 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -126.4 140.59 48.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-O 121.465 0.65 . . . . 0.0 110.353 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 73.3 m -81.25 146.1 30.61 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.539 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 18' ' ' ARG . 8.4 p -110.15 -173.48 2.26 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.339 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.515 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 14.8 m -55.76 -42.89 76.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.857 0.36 . . . . 0.0 111.483 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' GLY . 24.7 m . . . . . 0 C--O 1.247 0.973 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.35 -0.3 . . . . 0.0 112.35 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.628 ' SG ' ' HB3' ' A' ' 13' ' ' CYS . 5.8 t -86.3 -20.53 28.23 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 122.789 -0.242 . . . . 0.0 111.305 -179.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.695 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 1.6 pm0 -64.54 165.12 10.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.031 0.444 . . . . 0.0 111.144 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.32 15.48 64.27 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.33 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 2.0 mttm -131.46 167.54 19.16 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -96.79 149.07 22.26 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.114 0.483 . . . . 0.0 111.397 -178.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.722 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.8 p -130.13 -158.24 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.656 178.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 70.49 -106.61 1.9 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.532 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.3 mt -75.41 -67.94 0.61 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -83.29 64.83 7.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.6 179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.653 ' HA ' ' HA ' ' A' ' 7' ' ' CYS . 15.9 ptp180 -69.57 108.69 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.814 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -107.77 23.45 14.45 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.351 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.628 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 2.7 m -133.75 168.95 17.78 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.461 -178.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -99.55 -172.99 30.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.281 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -83.21 61.06 4.82 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.567 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.92 30.77 0.21 Allowed Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 1.4 m -140.07 149.54 43.24 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.473 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -80.51 121.81 26.24 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.531 0.205 . . . . 0.0 110.927 -178.605 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -91.67 97.48 11.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 21' ' ' PRO . 98.2 m95 -91.07 109.72 37.26 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.159 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 23.6 Cg_exo -63.24 147.93 93.47 Favored 'Trans proline' 0 C--O 1.232 0.212 0 C-N-CA 122.909 2.406 . . . . 0.0 112.672 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 75.3 p -106.09 -153.77 0.5 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.488 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.3 t -80.37 -20.53 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.1 0.476 . . . . 0.0 110.969 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.434 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.6 m -98.26 122.3 54.42 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.832 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 45.4 Cg_exo -56.76 112.07 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.984 2.456 . . . . 0.0 112.118 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.77 -16.84 30.76 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.605 -179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.434 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 48.8 t -98.47 129.83 48.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -155.97 163.57 31.89 Favored Glycine 0 N--CA 1.439 -1.14 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.7 tt -116.79 140.03 41.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 121.497 0.665 . . . . 0.0 111.122 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.722 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 63.7 m -80.96 147.41 30.27 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.919 -1.037 . . . . 0.0 111.354 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.695 ' HA ' ' HB3' ' A' ' 3' ' ' GLU . 9.4 t -119.39 -166.06 1.22 Allowed 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 177.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.87 -64.51 0.81 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.719 0.295 . . . . 0.0 111.317 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 49.5 m . . . . . 0 C--O 1.247 0.957 0 CA-C-O 117.724 -1.131 . . . . 0.0 108.988 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 12.1 t -106.93 29.24 7.22 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.206 0.526 . . . . 0.0 110.762 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.7 mp0 -77.03 160.04 29.41 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.328 -0.397 . . . . 0.0 109.985 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.46 36.57 49.13 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.403 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 30' ' ' CYS . 26.0 mmtm -131.94 167.66 19.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 19.3 mt-30 -132.2 153.99 50.03 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-O 121.364 0.602 . . . . 0.0 111.425 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.1 p -117.86 -55.38 2.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 27' ' ' VAL . . . -59.98 126.64 42.23 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.736 178.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 78.4 mt 70.41 -81.48 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.283 0.633 . . . . 0.0 110.222 -178.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -85.81 80.97 8.76 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.052 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -73.91 60.62 0.75 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.63 -178.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.7 m -94.3 64.02 3.13 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.411 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 2.2 t -130.77 173.33 11.03 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.953 -177.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -115.68 171.08 13.55 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.623 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.66 46.93 3.55 Favored Glycine 0 C--O 1.228 -0.24 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.588 -179.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -165.45 34.14 0.25 Allowed Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.411 ' HB2' ' SG ' ' A' ' 13' ' ' CYS . 1.1 m -138.12 141.63 40.19 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.693 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.612 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -82.45 125.71 31.39 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.942 -179.543 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 21.2 t -92.33 102.96 15.46 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.733 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 82.1 m95 -101.88 123.58 43.3 Favored Pre-proline 0 C--N 1.321 -0.636 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.917 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' TRP . 30.5 Cg_exo -60.18 147.03 94.96 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 123.016 2.477 . . . . 0.0 112.622 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.9 p -105.92 -153.56 0.49 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.821 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 t -76.0 -27.51 18.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.095 0.474 . . . . 0.0 111.19 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.409 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -90.03 121.43 68.79 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.646 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -58.24 108.04 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.979 2.453 . . . . 0.0 112.051 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 112.23 -11.47 26.52 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.538 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.409 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 99.1 t -103.5 135.54 40.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.91 159.4 28.08 Favored Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.66 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.7 tt -117.38 144.38 25.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.401 0.619 . . . . 0.0 111.239 -179.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 60.8 m -81.61 142.07 33.12 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.035 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.733 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.2 m -103.92 -174.64 2.59 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.529 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.3 m -49.18 -45.69 44.44 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.612 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 24.0 m . . . . . 0 C--O 1.245 0.86 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 -179.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.856 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.68 ' HB2' ' HB3' ' A' ' 13' ' ' CYS . 0.3 OUTLIER -118.5 43.83 2.4 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.347 179.311 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.6 mp0 -73.77 161.9 29.72 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.523 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.37 36.04 92.18 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.802 -0.635 . . . . 0.0 112.42 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mmtm -130.28 166.97 19.24 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' A' ' 11' ' ' ARG . 18.7 mt-30 -104.07 150.94 23.84 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.84 0.353 . . . . 0.0 110.603 -179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 28.5 p -124.02 -164.41 1.24 Allowed 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.415 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.79 -113.55 3.69 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.477 -0.868 . . . . 0.0 111.019 -178.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.581 ' HG ' ' H ' ' A' ' 10' ' ' PHE . 0.5 OUTLIER -85.86 -53.33 5.18 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.131 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.581 ' H ' ' HG ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -88.2 61.52 6.29 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.282 0.563 . . . . 0.0 109.983 179.277 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 0.0 OUTLIER -74.1 125.53 28.53 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.387 0.613 . . . . 0.0 111.631 -178.753 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.71 20.29 14.08 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.159 178.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.68 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 0.1 OUTLIER -141.49 169.85 16.83 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.889 -1.05 . . . . 0.0 109.851 -179.526 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -134.71 -150.91 6.21 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.344 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.95 132.89 43.4 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.449 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . 123.83 -30.02 4.98 Favored Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.466 ' SG ' ' N ' ' A' ' 2' ' ' CYS . 65.1 m -113.91 143.13 45.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.406 0.622 . . . . 0.0 110.434 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.651 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -83.68 147.16 27.84 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.316 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.8 t -95.53 94.99 8.1 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -94.37 111.77 54.95 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.273 -178.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.12 149.73 89.36 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.104 2.536 . . . . 0.0 112.81 -179.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.404 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 64.0 p -103.08 -152.29 0.45 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.615 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.404 ' H ' ' HB ' ' A' ' 22' ' ' THR . 4.5 t -79.93 -21.6 11.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.215 0.531 . . . . 0.0 110.954 -179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.455 ' HB ' ' CG2' ' A' ' 27' ' ' VAL . 1.3 m -97.66 121.83 56.92 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' THR . 43.0 Cg_exo -56.86 112.12 1.0 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.954 2.436 . . . . 0.0 112.132 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.4 -20.09 23.55 Favored Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 39.5 t -96.37 127.27 48.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -147.96 166.75 28.88 Favored Glycine 0 N--CA 1.439 -1.116 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.8 tt -131.02 140.55 48.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-O 121.382 0.611 . . . . 0.0 111.066 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.651 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 95.0 m -81.51 141.62 33.65 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.8 m -112.73 -174.13 2.39 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.16 -179.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 70.0 m -61.3 -34.37 75.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.967 0.413 . . . . 0.0 111.905 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.62 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 19.6 m . . . . . 0 C--O 1.249 1.055 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 32' ' ' SER . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 30' ' ' CYS . 77.9 m -113.81 29.73 7.78 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.641 -0.329 . . . . 0.0 110.785 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 30' ' ' CYS . 20.6 mp0 -60.48 153.03 24.23 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.006 0.432 . . . . 0.0 110.962 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.98 15.87 76.43 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.515 -0.766 . . . . 0.0 113.135 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 42.7 mttp -123.04 166.85 14.44 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 117.119 0.46 . . . . 0.0 110.103 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -112.53 136.25 52.28 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.037 -178.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.692 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 22.7 p -117.58 178.75 4.28 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.496 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 144.13 -174.35 24.49 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.863 HD13 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -80.27 4.95 16.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.198 0.523 . . . . 0.0 111.117 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' HD1' HD22 ' A' ' 9' ' ' LEU . 6.6 p90 -132.24 16.39 4.56 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.606 -0.725 . . . . 0.0 109.519 179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 24.7 mmm180 -130.45 176.36 8.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.945 -178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -139.09 137.73 36.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.34 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.14 171.88 19.07 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -73.03 152.94 47.83 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.33 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.87 75.99 Favored Glycine 0 C--O 1.228 -0.235 0 C-N-CA 121.079 -0.582 . . . . 0.0 112.548 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -108.27 35.89 4.7 Favored Glycine 0 N--CA 1.447 -0.593 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 33' ' ' SER . 5.0 m -136.43 146.8 46.8 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.683 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 0.0 OUTLIER -82.2 155.45 24.92 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.212 -178.109 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 38.5 t -124.37 88.79 2.96 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.675 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 96.2 m95 -87.14 115.5 62.87 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.407 -179.35 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.35 149.21 87.18 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.023 2.482 . . . . 0.0 112.721 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 23' ' ' VAL . 44.1 p -108.16 -150.34 0.45 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.548 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.406 ' H ' ' HB ' ' A' ' 22' ' ' THR . 5.6 t -79.83 -22.35 11.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.158 0.504 . . . . 0.0 110.944 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.49 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 0.8 OUTLIER -94.51 122.89 59.96 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.729 -179.688 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 24' ' ' THR . 19.4 Cg_endo -59.28 108.71 0.46 Allowed 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.865 2.377 . . . . 0.0 112.041 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.04 -10.28 31.69 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.623 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 97.7 t -105.94 132.69 52.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -149.39 178.07 27.15 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.548 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 5' ' ' LYS . 2.3 tt -122.36 137.94 54.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.698 0.761 . . . . 0.0 111.031 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.692 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 57.1 m -80.65 138.46 36.4 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.534 -1.212 . . . . 0.0 109.956 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.675 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 0.7 OUTLIER -117.65 -165.56 1.1 Allowed 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.166 -179.54 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 12.9 m -57.63 -65.83 0.57 Allowed 'General case' 0 C--N 1.327 -0.392 0 O-C-N 123.216 0.322 . . . . 0.0 111.21 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 55.2 m . . . . . 0 C--O 1.247 0.952 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.111 0 N-CA-C 112.333 -0.307 . . . . 0.0 112.333 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.549 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 10.9 p -122.84 -17.53 6.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.879 0.371 . . . . 0.0 110.283 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.603 ' CD ' ' H ' ' A' ' 3' ' ' GLU . 1.3 mp0 -60.08 143.23 52.6 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 179.113 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 89.35 -11.36 70.03 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.961 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.549 ' HD2' ' HA ' ' A' ' 2' ' ' CYS . 82.5 mttt -88.45 171.25 10.24 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.233 0.539 . . . . 0.0 110.83 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 50.6 tt0 -97.62 142.49 29.37 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.678 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.485 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -128.61 -171.36 2.45 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.099 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.86 -121.08 5.9 Favored Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 111.006 -0.837 . . . . 0.0 111.006 -179.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.55 ' HG ' ' HD1' ' A' ' 10' ' ' PHE . 1.1 pt? -58.32 -42.3 86.45 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.135 0.493 . . . . 0.0 109.768 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HD1' ' HG ' ' A' ' 9' ' ' LEU . 23.1 p90 -132.81 130.01 39.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.14 136.86 47.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.829 0.347 . . . . 0.0 111.456 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.98 31.29 3.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.918 0.866 . . . . 0.0 108.84 178.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.523 ' HB3' ' HB2' ' A' ' 2' ' ' CYS . 3.4 m -128.2 153.13 47.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.921 -178.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -93.34 -170.21 39.33 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.237 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.29 54.68 4.56 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.569 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' SER . . . -154.65 23.65 0.64 Allowed Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.5 m -139.15 145.49 39.44 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.59 ' HB2' ' OXT' ' A' ' 33' ' ' SER . 0.0 OUTLIER -81.15 134.61 35.66 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.465 -179.298 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -103.3 94.17 5.36 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.697 ' HD1' ' HG ' ' A' ' 31' ' ' SER . 89.8 m95 -91.57 120.73 68.09 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.876 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.94 156.34 58.94 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.727 2.284 . . . . 0.0 113.304 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.47 HG23 ' HA2' ' A' ' 28' ' ' GLY . 50.7 p -114.86 -151.01 0.47 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.614 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.6 t -80.1 -23.48 11.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.121 0.486 . . . . 0.0 111.04 -179.516 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.528 ' HB ' ' HB ' ' A' ' 27' ' ' VAL . 1.5 m -93.87 123.66 58.88 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.695 -179.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.6 112.0 1.05 Allowed 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.934 2.423 . . . . 0.0 112.026 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.88 -4.94 46.23 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.676 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HB ' ' HB ' ' A' ' 24' ' ' THR . 98.7 t -110.52 134.27 53.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.617 -0.291 . . . . 0.0 110.233 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.47 ' HA2' HG23 ' A' ' 22' ' ' THR . . . -152.01 -173.44 21.67 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 1.5 tt -133.63 141.39 44.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.253 0.549 . . . . 0.0 111.151 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 18' ' ' ARG . 40.1 m -80.68 136.11 36.13 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.9 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.697 ' HG ' ' HD1' ' A' ' 20' ' ' TRP . 1.5 m -103.62 -174.15 2.48 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.046 -0.979 . . . . 0.0 109.439 179.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.468 ' HA ' ' HG3' ' A' ' 3' ' ' GLU . 1.4 m -55.58 -50.92 68.81 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.59 ' OXT' ' HB2' ' A' ' 18' ' ' ARG . 16.3 m . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.022 -0.513 . . . . 0.0 109.717 -179.61 . . . . . . . . 1 1 . 1 stop_ save_